1. Biperidene Lactate
1. Akineton
2. 09td6c5147
3. 1-piperidinepropanol, Alpha-bicyclo(2.2.1)hept-5-en-2-yl-alpha-phenyl-, Compd. With 2-hydroxypropanoic Acid (1:1)
4. Tasmolin (tn)
5. Akineton Lactate
6. Einecs 230-388-9
7. Biperidenlactat
8. Unii-09td6c5147
9. Biperiden Lactate [usp:ban:jan]
10. Biperidenlactate
11. Alpha-5-norbornen-2-yl-alpha-phenyl-1-piperidinepropanol Lactate (salt)
12. Alpha-5-norbornen-2-yl-alpha-phenyl-1-piperidinepropanol Compd. With Lactic Acid (1:1)
13. Schembl41834
14. Biperiden Lactate (jan/usp)
15. Biperiden Lactate [jan]
16. Chembl1201067
17. Biperiden Lactate [vandf]
18. Dtxsid40991120
19. Biperiden Lactate [mart.]
20. Biperiden Lactate [who-dd]
21. Hy-13204b
22. Biperiden Lactate [orange Book]
23. Biperiden Lactate [usp Impurity]
24. Lactic Acid, Compd. With Alpha-5-norbornen-2-yl-alpha-phenyl-1-piperidinepropanol (1:1)
25. Lactic Acid, Compound With Alpha-bicyclo(2.2.1)hept-5-en-2-yl-alpha-phenylpiperidin-1-propanol (1:1)
26. Cs-0030940
27. D02247
28. Q27236503
29. .alpha.-5-norbornen-2-yl-.alpha.-phenyl-1-piperidinepropanol Lactate (salt)
30. 1-(2-bicyclo[2.2.1]hept-5-enyl)-1-phenyl-3-piperidin-1-ylpropan-1-ol;2-hydroxypropanoic Acid
31. 1-piperidinepropanol, .alpha.-bicyclo(2.2.1)hept-5-en-2-yl-.alpha.-phenyl-, Compd. With 2-hydroxypropanoic Acid (1:1)
Molecular Weight | 401.5 g/mol |
---|---|
Molecular Formula | C24H35NO4 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 6 |
Exact Mass | 401.25660860 g/mol |
Monoisotopic Mass | 401.25660860 g/mol |
Topological Polar Surface Area | 81 Ų |
Heavy Atom Count | 29 |
Formal Charge | 0 |
Complexity | 481 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 5 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Muscarinic Antagonists
Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)
Antiparkinson Agents
Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. (See all compounds classified as Antiparkinson Agents.)
Parasympatholytics
Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. (See all compounds classified as Parasympatholytics.)
LOOKING FOR A SUPPLIER?